NorthCrest Asset Manangement LLC Acquires 2,876 Shares of Johnson & Johnson (NYSE:JNJ)

NorthCrest Asset Manangement LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 235,695 shares of the company's stock after buying an additional 2,876 shares during the period. Johnson & Johnson makes up about 1.0% of NorthCrest Asset Manangement LLC's investment portfolio, making the stock its 20th largest holding. NorthCrest Asset Manangement LLC's holdings in Johnson & Johnson were worth $34,086,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $32,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at $36,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.41 during mid-day trading on Friday, hitting $154.99. The company's stock had a trading volume of 15,529,047 shares, compared to its average volume of 7,975,430. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $372.92 billion, a price-to-earnings ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The stock has a fifty day moving average of $154.31 and a 200-day moving average of $153.65.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Analysts Set New Price Targets

Several equities analysts have recently commented on JNJ shares. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Raymond James lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.